Trospium Chloride (trospium chloride)

Advertisement

Last reviewed · Source: First Databank (FDB) drug data

Overview

Trospium chloride, a quaternary ammonium antimuscarinic, is a genitourinary antispasmodic.

Trospium chloride, a quaternary ammonium antimuscarinic, antagonizes acetylcholine at muscarinic receptors in cholinergically innervated organs. Its parasympatholytic action reduces the tonus of smooth muscle in the urinary bladder. In urodynamic studies in patients with conditions characterized by involuntary detrusor contractions, trospium increased maximum cystometric capacity and volume at first detrusor contraction.

At concentrations achieved following usual therapeutic doses of the drug, trospium has little or no affinity for nicotinic receptors compared with muscarinic receptors.

Trospium chloride is incompletely absorbed from the GI tract following oral administration. The mean absolute oral bioavailability is about 9.6%. Administration of trospium chloride with a high-fat meal reduces systemic exposure to and peak plasma concentrations of the drug by about 70-80%.

The drug is hydrophilic and theoretically should not cross the blood-brain barrier like lipophilic anticholinergic drugs (e.g., oxybutynin, tolterodine); therefore, adverse CNS effects (e.g., dizziness) should be minimal. Following oral administration of radiolabeled trospium chloride, approximately 85% of the dose was excreted in feces and about 5.8% was eliminated in urine; unchanged drug accounted for about 60% of the recovered radioactivity in urine. Active tubular secretion is a major route of elimination of trospium, implying possible competition for renal secretion with other drugs that are eliminated by the same route. (See Drug Interactions.) Metabolic pathways of trospium have not been fully elucidated to date; however, the cytochrome P-450 (CYP) enzyme system is not expected to contribute substantially to elimination of the drug.

Based on in vitro studies, trospium does not appear likely to inhibit CYP isoenzymes 1A2, 3A4, 2A6, 2C9, 2C19, 2D6, or 2E1 at clinically relevant concentrations.

USES: This medication is used to treat an overactive bladder. By relaxing the muscles in the bladder, trospium improves your ability to control your urination. It helps to reduce leaking of urine, feelings of needing to urinate right away, and frequent trips to the bathroom.

Trospium belongs to a class of drugs known as antispasmodics. It is also known as an antimuscarinic.

Generic name: trospium chloride
Pronunciation: (TROSE-pee-um)

Reference product & biosimilars

No reference, biosimilar or interchangeable associated with this drug.

Today’s intelligence on Trospium Chloride

Intelligence content is not available yet.

Indications

The following indications are listed for Trospium Chloride:

  • Bladder Hyperactivity
  • Increased Urinary Frequency
  • Urinary Urge Incontinence
  • Urinary Urgency

Also known as: Detrusor Overactivity, Hypertonic Bladder, Hypertonicity Of Bladder, Low Compliance Of Bladder, Overactive Detrusor, Urge Incontinence, Urge Urinary Incontinence, Urinary Frequency.

Dosing

No dosing information is available for this tab.

Drug interactions

There is no enhanced messaging for this drug.

Contraindications

Urinary retention, gastric retention, or uncontrolled angle-closure glaucoma or risk of these conditions.

Known hypersensitivity to trospium chloride or any ingredient in the formulation.

Adverse reactions

Adverse effects occurring in 5% or more of patients receiving trospium include dry mouth and constipation.

Precautions

No enhanced messaging available.

ICD codes

No ICD codes are available for this drug.

Formulary status

Search health-plan coverage for this drug by ZIP code.

Enter a ZIP code to view available health plans.

Last reviewed · Source: First Databank (FDB) drug data